Hypothermic and antipyretic effects of centrally administered ACTH (1--24) and alpha-melanotropin.
ACTH (1--24) and alpha-melanotropin (alpha-MSH), peptides previously shown to influence body temperature when administered centrally and to occur naturally in brain regions important to temperature control, were injected intracerebroventricularly (ICV) in rabbits. The peptides in doses of 1.25, 2.5 and 5.0 micrograms produced dose-related hypothermias in a 23 degrees C environment, and greater decreases in body temperature when the experiments were repeated in the cold (10 degrees C), but the largest dose had no effect on temperature in the heat (30 degrees C). These results indicate that the peptides do not reduce the central set-point of temperature control. Rather, they appear to selectively inhibit heat conservation and production responses. Five microgram of ACTH reversed vasoconstriction and inhibited rises in temperature caused by leukocytic pyrogen (LP) given IV and ICV. The same dose of alpha-MSH also reduced fever produced by IV and ICV LP, but the reduction was not as great as after ACTH. Both peptides (5 micrograms) also reduced temperature rises and vasoconstriction caused by ICV PGE2. ACTH reduced d-amphetamine-induced hyperthermia without altering vasoconstriction which suggests that this peptide can reduce temperature rises by inhibiting heat production alone. One of the most important findings was that the peptides are antipyretic in that they reduce fever at doses (0.25 microgram, ICV) that do not affect normal temperature. The powerful effects of these peptides on resting body temperature, hyperthermia and fever, together with their presence in brain tissue important to temperature control, suggest that the endogenous central peptides participate in thermoregulation, perhaps by limiting fever and influencing normal temperature.
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives*; D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D001833:Body Temperature Regulation / Q000187:drug effects*; D003366:Cosyntropin / Q000494:pharmacology*; D003913:Dextroamphetamine / Q000494:pharmacology; D007375:Interleukin-1; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology; D011506:Proteins / Q000494:pharmacology; D011749:Pyrogens / Q000494:pharmacology; D051381:Rats; D014661:Vasoconstriction / Q000187:drug effects
D007375:Interleukin-1; D011458:Prostaglandins E; D011506:Proteins; D011749:Pyrogens; C008270:leukocyte endogenous mediator; D003366:Cosyntropin; D000324:Adrenocorticotropic Hormone; D009074:Melanocyte-Stimulating Hormones; D003913:Dextroamphetamine